Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE)



Status:Completed
Conditions:Asthma
Therapuetic Areas:Pulmonary / Respiratory Diseases
Healthy:No
Age Range:18 - 90
Updated:1/25/2018
Start Date:December 2004
End Date:February 2008

Use our guide to learn which trials are right for you!

The purpose of this trial is to determine whether regularly scheduled use of an inhaled
long-acting beta agonist (salmeterol) in the setting of concomitant use of inhaled
corticosteroids (beclomethasone hydroflouroalkane (HFA) inhaler) will have a detrimental
effect on asthma control in people who bear the B16-Arg/Arg genotype of the beta-2 adrenergic
receptor gene, as compared to people with asthma of similar severity who bear the B16-Gly/Gly
genotype.

BACKGROUND:

The purpose of this study is to compare the effects of a long-acting beta agonist in patients
with asthma receiving inhaled corticosteroids who express two distinct polymorphisms of the
beta-2 adrenergic receptor.

DESIGN NARRATIVE:

Participants were homozygous for arginine or glycine at the 16th amino-acid position of the
β-2 adrenergic receptor (B16 Arg/Arg or B16 Gly/Gly). Individuals were matched against their
opposite genotype by forced expiratory volume in one second (FEV1) and race. Matched
participants entered an 8-week run-in period. This is a 62-week crossover design where
subjects receive the following therapies:

- Beclomethasone HFA (240 µg twice a day (BID)) + as-needed (PRN) albuterol: 8-week run-in

- Beclomethasone HFA (240 µg BID) + salmeterol (50 µg BID) + PRN ipratropium bromide + PRN
albuterol: 18-week treatment period

- Beclomethasone HFA (240 µg BID) + PRN albuterol: 8-week run-out

- Beclomethasone HFA (240 µg BID) + placebo salmeterol + PRN ipratropium bromide + PRN
albuterol: 18-week treatment period

- Beclomethasone HFA (240 µg BID) + PRN albuterol: 10-week run-out

The order of treatments received during the two treatment periods is randomized.

Inclusion Criteria:

- Male or female, ages 18 and older

- Clinical history consistent with asthma

- For subjects regularly using inhaled corticosteroids, FEV1 50% of predicted,
methacholine PC20 FEV1 16 mg/ml or 12% and 200 ml, improvement in FEV1 after 2 puffs
of inhaled albuterol

- For subjects not regularly using inhaled corticosteroids, FEV1 40% of predicted,
methacholine PC20 FEV1 8 mg/ml or 12% and 200 ml, improvement in FEV1 after 2 puffs of
inhaled albuterol

- Genotype eligibility (determined during screening)

Exclusion Criteria:

- Smoker (total smoking history must be less than 10 pack years)

- Significant unstable medical condition other than asthma

- History of life-threatening asthma requiring treatment with intubation and mechanical
ventilation in the past 10 years

- Pregnant or lactating
We found this trial at
7
sites
San Diego, California 92093
?
mi
from
San Diego, CA
Click here to add this to my saved trials
75 Francis street
Boston, Massachusetts 02115
(617) 732-5500
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Denver, CO
Click here to add this to my saved trials
Madison, Wisconsin 53706
(608) 263-2400
University of Wisconsin-Madison In achievement and prestige, the University of Wisconsin-Madison has long been recognized...
?
mi
from
Madison, WI
Click here to add this to my saved trials
Saint Louis, Missouri 63110
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
San Francisco, California 94143
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
1 Medical Center Blvd
Winston-Salem, North Carolina 27157
336-716-2011
Wake Forest University Health Sciences Welcome to Wake Forest Baptist Medical Center, a fully integrated...
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials